BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
Werte in diesem Artikel
SAN RAFAEL, Calif., Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA.
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-td-cowen-45th-annual-healthcare-conference-on-tuesday-march-4-at-650-am-pt--950-am-et-in-boston-ma-302383918.html
SOURCE BioMarin Pharmaceutical Inc.
Ausgewählte Hebelprodukte auf Biomarin Pharmaceutical
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Biomarin Pharmaceutical
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Biomarin Pharmaceutical Aktie News
Biomarin Pharmaceutical Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Biomarin Pharmaceutical nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.12.18 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
| 01.10.18 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
| 07.08.18 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
| 03.08.18 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
| 16.05.18 | Biomarin Pharmaceutical Buy | Canaccord Adams |
